On May 10, 2021 Irish based cell engineering company, Avectas reported the publication of ‘A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications’ in leading international cell and gene therapy publication, Cytotherapy (Press release, Avectas, MAY 10, 2021, View Source [SID1234579622]).1
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cytotherapy is the official journal of the International Cell & Gene Therapy Society (ISCT).
Dr Shirley O’Dea et al. examined the suitability of Avectas’ SOLUPORE non-viral delivery system for engineering primary human T cells for cell therapy applications. This publication describes how the next generation of immune cell therapy products will require complex modifications using engineering technologies that can maintain high levels of cell functionality and how non-viral engineering methods such as SOLUPORE have the potential to address limitations associated with viral vectors.
Data demonstrates efficient transfection of human primary T Cells with mRNA and CRISPR CAS9 RNP cargos while consistently maintaining high levels of cell viability. Gene expression profiling revealed minimal up or down regulation of genes, demonstrating the low level of perturbation experienced by the cells during this transfection process in contrast to electroporation which resulted in substantial changes in immune gene expression. CAR T cells engineered using the SOLUPORE system exhibited high cytotoxicity against target cancer cells in vitro and in vivo.
Avectas has previously published on the SOLUPORE Technology in PLOS ONE2 with citations in both Nature Biomedical Engineering3 and Chemical Reviews4.
Commenting on the publication, Dr Michael Maguire, CEO of Avectas, said: "It is impressive to see further published evidence showing the advantages of the SOLUPORE platform in preserving cellular functionality essential for cell therapies. Congratulations to Avectas CSO, Dr Shirley O’Dea and the Avectas R&D team on this additional publication of important work to support the efficacy and potential of SOLUPORE technology to the cell and gene therapy industry."
Using its patented SOLUPORE technology, Avectas partners with leading cell and gene therapy companies and research institutions to enable the next-generation of gene-modified cell therapies.